1. Sung, H, Ferlay, J, Siegel, RL, et al. Global cancer statistics 2020: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249
Google Scholar | Crossref | Medline2. Yoon, SM, Ryoo, BY, Lee, SJ, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy versus sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial. JAMA Oncol. 2018;4(5):661-669.
Google Scholar | Crossref | Medline3. Llovet, JM, Ricci, S, Mazzaferro, V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-390.
Google Scholar | Crossref | Medline | ISI4. Cheng, AL, Kang, YK, Chen, Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25-34.
Google Scholar | Crossref | Medline | ISI5. Kudo, M, Finn, RS, Qin, S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163-1173.
Google Scholar | Crossref | Medline6. El-Khoueiry, AB, Sangro, B, Yau, T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492-2502.
Google Scholar | Crossref | Medline7. Zhu, AX, Finn, RS, Edeline, J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940-952.
Google Scholar | Crossref | Medline8. Keam, SJ . Toripalimab: first global approval. Drugs. 2019;79(5):573-578.
Google Scholar | Crossref | Medline9. Finn, RS, Ryoo, BY, Merle, P, et al. Pembrolizumab As second-line therapy in patients With advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38(3):193-202.
Google Scholar | Crossref | Medline10. Yau, T, Park, JW, Finn, RS, et al. Checkmate 459: a randomized, multi-center phase III study of nivolumab (NIVO) versus sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2019;30:v874-v875.
Google Scholar | Crossref11. Lesterhuis, WJ, Punt, CJ, Hato, SV, et al. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest. 2011;121(8):3100-3108.
Google Scholar | Crossref | Medline12. Liu, WM, Fowler, DW, Smith, P, et al. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer. 2010;102(1):115-123.
Google Scholar | Crossref | Medline13. Zhou, C, Chen, G, Huang, Y, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med. 2021;9(3):305-314.
Google Scholar | Crossref | Medline14. Mai, HQ, Chen, QY, Chen, D, et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med. 2021;27(9):1535-1537.
Google Scholar | Crossref15. Johnson, PJ . Systemic chemotherapy of liver tumors. Semin Surg Oncol. 2000;19(2):116-124.
Google Scholar | Crossref | Medline16. Lyu, N, Kong, Y, Mu, L, et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin versus sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2018;69(1):60-69.
Google Scholar | Crossref | Medline17. Kudo, M, Matsui, O, Izumi, N, et al. JSH Consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the liver cancer study group of Japan. Liver Cancer. 2014;3(3-4):458-468.
Google Scholar | Crossref | Medline | ISI18. Chen, L, Martinelli, E, Cheng, A, et al. Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol. 2020;31(3):334-351.
Google Scholar | Crossref | Medline19. Eisenhauer, EA, Therasse, P, Bogaerts, J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
Google Scholar | Crossref | Medline | ISI20. Stuart, EA . Matching methods for causal inference: a review and a look forward. Stat Sci. 2010;25(1):1-21.
Google Scholar | Crossref | Medline | ISI21. Hill, J . Discussion of research using propensity-score matching: comments on ‘A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003’ by peter Austin, statistics in medicine. Stat Med. 2008;27(12):2055-2061; discussion 2066-2059.
Google Scholar | Crossref | Medline22. Mathew, M, Enzler, T, Shu, CA, et al. Combining chemotherapy with PD-1 blockade in NSCLC. Pharmacol Ther. 2018;186:130-137.
Google Scholar | Crossref | Medline23. Bruix, J, Cheng, AL, Meinhardt, G, et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J Hepatol. 2017;67(5):999-1008.
Google Scholar | Crossref | Medline24. Finn, RS, Qin, S, Ikeda, M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894-1905.
Google Scholar | Crossref | Medline25. Forner, A, Reig, M, Bruix, J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301-1314.
Google Scholar | Crossref | Medline26. Heimbach, JK, Kulik, LM, Finn, RS, et al. AASLD Guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358-380.
Google Scholar | Crossref | Medline27. European Association for the Study of the Liver . Electronic address EEE, European Association for the Study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182-236.
Google Scholar | Crossref | Medline28. Lyu, N, Zhao, M. Hepatic arterial infusion chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase 3 trial (The FOHAIC-1 study). J Clin Oncol. 2021;39(15_suppl):4007.
Google Scholar | Crossref29. MinKe He SMZLQL . A phase II trial of lenvatinib plus toripalimab and hepatic arterial infusion chemotherapy as a first-line treatment for advanced hepatocellular carcinoma (LTHAIC study). In MinKe He SMZLQL, Department of Hepatobiliary Oncology SY-sUCCSKLoOiSCCICfCMGC, Department of Hepatobiliary Oncology SY-sUCCSKLoOiSCCICfCMGVAC, (Eds). ASCO Annual Meeting: American Society of Clinical Oncology .
Google Scholar30. He, MK, Liang, RB, Zhao, Y, et al. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma. Ther Adv Med Oncol. 2021;13:1-14.
Google Scholar | SAGE Journals31. Mei, J, Li, SH, Li, QJ, et al. Anti-PD-1 immunotherapy improves the efficacy of hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;8:167-176.
Google Scholar | Crossref | Medline32. Yu, MC, Yuan, JM, Govindarajan, S, et al. Epidemiology of hepatocellular carcinoma. Can J Gastroenterol. 2000;14(8):703-709.
Google Scholar | Crossref | Medline